Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | XBP1 | P17861 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | GRK2 | P25098 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27863512 | 0.89 | MAPT (0.55) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL965055 | 0.85 | ALDH1A1 (0.57) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL1451069 | 0.85 | MAPT (0.58) | MAPTMEN1KMT2AHTTRAB9A | |
| Hydrochloric Acid SCHEMBL9738365 | 0.84 | MAPT (0.53) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL14065404 | 0.83 | HDAC8 (0.50) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL30366730 | 0.83 | ALDH1A1 (0.61) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL9584096 | 0.83 | SMN1; SMN2 (0.59) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL10382109 | 0.83 | MAPT (0.54) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL1441279 | 0.82 | LMNA (0.57) | MAPTALDH1A1LMNA | |
| SCHEMBL340537 | 0.82 | AKR1C3 (0.55) | MAPTMEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024130161-A2 | NOVEL CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | BIONECURE THERAPEUTICS INC (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| US-11753445-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230218710-A1 | METHOD OF TREATING CORONAVIRUS INFECTIONS | COHBAR, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230137562-A1 | TAU AGGREGATION INHIBITORS | ADRX, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4135738-A2 | METHOD OF TREATING CORONAVIRUS INFECTIONS | Cohbar Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20220395553-A1 | CXCR4 ANTAGONIST PEPTIDES | COHBAR, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220332774-A1 | THERAPEUTIC MITOCHONDRIAL PEPTIDES | COHBAR, INC. | 2022-10-20 | — | — | US | disclosed |
| US-20220324909-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324925-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20040014082-A1 | Highly homogeneous molecular markers for electrophoresis | INVITROGEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-6566338-B1 | Administering caspase inhibitor for therapy of oral mucositis, gastrointestinal mucositis, bladder mucositis or proctitis resulting from chemotherapy or radiation therapy of cancer in an animal | CYTOVIA, INC. | 2003-05-20 | — | — | US | disclosed |
| EP-1076563-A4 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20020155455-A1 | Highly homogeneous molecular markers for electrophoresis | INVITROGEN CORPORATION | 2002-10-24 | — | — | US | disclosed |
| EP-1220869-A1 | CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH | Cytovia, Inc. (US) | 2002-07-10 | — | — | EP | disclosed |
| CN-1297354-A | Dipeptide caspase inhibitors and use thereof | CYTOVIA INC (US) | 2001-05-30 | — | — | CN | disclosed |
| WO-2001027140-A1 | CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH | CYTOVIA, INC. (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-1076563-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| US-6153591-A | PROTECTING NERVOUS SYSTEM FOLLOWING FOCAL ISCHEMIA AND GLOBAL ISCHEMIA; ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PRION DISEASES, PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS, ALOPACIA, RHEUMATOID ARTHRITIS | CYTOVIA, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-1999047154-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014082-A1 | Highly homogeneous molecular markers for electrophoresis | CD44, HLA-C, HLA-A | MAPT 3603/4885MEN1 4311/4885KMT2A 3634/4885 |
| US-20020155455-A1 | Highly homogeneous molecular markers for electrophoresis | CD44, HLA-C, HLA-A | MAPT 3603/4885MEN1 4311/4885KMT2A 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.